This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.
Study Type
OBSERVATIONAL
Enrollment
300
Progression-free survival, defined as time from first administration of first-line therapy to documented disease progression
Time frame: approximately 6 years
Safety: Incidence of adverse events
Time frame: approximately 6 years
Overall survival, defined as time from first administration of first-line therapy to documented death
Time frame: approximately 6 years
Objective response rate, defined as percentage of patients with complete or partial response according to local assessments
Time frame: approximately 6 years
Quality of life: EQ-5D/EORTC questionnaires
Time frame: approximately 6 years
Dosage/schedule/duration of Avastin therapy
Time frame: approximately 6 years
Composition of first-line chemotherapy regimens: drugs/dosage/duration
Time frame: approximately 6 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Royal United Hospital; Oncology Department
Bath, United Kingdom
City Hospital
Birmingham, United Kingdom
Bradford Royal Infirmary; Oncology Department
Bradford, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, United Kingdom
Queen's Hospital; Oncology Department
Burton-on-Trent, United Kingdom
Essex County Hospital
Colchester, United Kingdom
Eastborne District General Hospital
Eastbourne, United Kingdom
Wonford Hospital; Oncology Department
Exeter, United Kingdom
Royal Surrey County Hospital
Guildford, United Kingdom
Ipswich Hospital
Ipswich, United Kingdom
...and 20 more locations